Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer treatment has advanced with CDK4/6 inhibitors.
• Variable patient responses and acquired resistance to CDK4/6 inhibitors present significant clinical challenges.

Purpose of the Study:

• To comprehensively define the molecular response to palbociclib, a widely used CDK4/6 inhibitor, in breast cancer cells.
• To identify mechanisms underlying response variability and resistance to CDK4/6 inhibition.
• To nominate novel combination therapies based on elucidated molecular pathways.

Main Methods:

• Global gene expression profiling.
• Proteomic analysis of protein abundance.
• Alternative splicing analysis.
• Chromatin accessibility assays (ATAC-seq).

Main Results:

• CDK4/6 inhibition induces broad molecular changes, including gene expression, protein levels, and alternative splicing.
• An unexpected feedback loop between CDK4/6 and estrogen receptor signaling was identified.
• A widespread alternative splicing program impacting protein function was uncovered.
• Co-targeting CDK7, which regulates CDK2, CDK4/6, and ERα, showed additive effects on cell fitness.

Conclusions:

• The response to CDK4/6 inhibitors is complex and multi-tiered, involving intricate signaling networks.
• Understanding these molecular alterations provides insights into therapeutic efficacy and resistance mechanisms.
• Targeting feedback loops and utilizing combination therapies, such as with CDK7 inhibitors, may overcome resistance and improve treatment outcomes in HR+/HER2- breast cancer.